David Sans

About David Sans

David Sans, FAARM, Ph.D., M.B.A., is a Chemical Engineer with a PhD in Chemometrics and Artificial Intelligence from Dr. Stoessel's laboratory at the ETH in Zurich and a Mount Sinai Board Certification in Cell Therapies. David holds FINRA Series 7, 63, 15, and 55 licenses for Healthcare Investment Banking. David has over 12 years of expertise in Healthcare Investment Banking, providing the entire range of investment banking advisory services such as M&A, project finance, capital raising, and exceptional situations. David's customers have completed over 100 Healthcare Investment Banking transactions since 2008, providing superior services to financial institutions, healthcare institutional investors, and strategic partners. David founded the AI Pathology platform at Mount Sinai Hospital in New York in 2012 and sold it to Philips in 2021, among other things. Annovis Bio is one of David's IPOs, with a $600 million value creation from its $10 million IPO in December 2020. David worked as the Vice President of Finance and Investment Strategy at ImClone Systems, reporting to the CEO and the Board of Directors, and as the Managing Director of Healthcare Banking at ThinkEquity. David began his career as a Sr. Medical Scientist at Novartis during the introduction of Glivec® (Imatinib) in Switzerland, then moved on to Pfizer as the Director of Market Analytics for the launch of Rebif® (interferon beta-1a for MS) and Macugen.